Sleep architecture as correlate and predictor of symptoms and impairment in inter-episode bipolar disorder: taking on the challenge of medication effects

J Sleep Res. 2010 Dec;19(4):516-24. doi: 10.1111/j.1365-2869.2010.00826.x.

Abstract

This study was designed to clarify the association between inter-episode bipolar disorder (BD) and sleep architecture. Participants completed a baseline symptom and sleep assessment and, 3 months later, an assessment of symptoms and impairment. The effects of psychiatric medications on sleep architecture were also considered. Participants included 22 adults with BD I or II (inter-episode) and 22 non-psychiatric controls. The sleep assessment was conducted at the Sleep and Psychological Disorders Laboratory at the University of California, Berkeley. Follow-up assessments 3 months later were conducted over the phone. Results indicate that, at the sleep assessment, BD participants exhibited greater rapid eye movement sleep (REM) density than control participants with no other group differences in sleep architecture. Sleep architecture was not correlated with concurrent mood symptoms in either group. In the BD group, duration of the first REM period and slow-wave sleep (SWS) amount were positively correlated with manic symptoms and impairment at 3 months, while REM density was positively correlated with depressive symptoms and impairment at 3 months. The amount of Stage 2 sleep was negatively correlated with manic symptoms and impairment at 3 months. In contrast, for the control group, REM density was negatively correlated with impairment at 3 months. SWS and Stage 2 sleep were not correlated with symptoms or impairment. Study findings suggest that inter-episode REM sleep, SWS and Stage 2 sleep are correlated with future manic and depressive symptoms and impairment in BD. This is consistent with the proposition that sleep architecture may be a mechanism of illness maintenance in BD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antimanic Agents / adverse effects
  • Antimanic Agents / therapeutic use
  • Bipolar Disorder / complications*
  • Bipolar Disorder / drug therapy
  • Bipolar Disorder / physiopathology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Polysomnography
  • Sleep / drug effects
  • Sleep / physiology
  • Sleep Wake Disorders / complications*
  • Sleep Wake Disorders / etiology
  • Sleep Wake Disorders / physiopathology
  • Sleep, REM / drug effects
  • Sleep, REM / physiology
  • Young Adult

Substances

  • Antimanic Agents